Thymosin Alpha-1

Also: Tα1, Thymosin α1, Thymosin alpha 1, Thymalfasin, Zadaxin, TA1

Immunomodulatory peptideLimitedStudied in preclinical (in vitro and animal) and some clinical research settings, with a synthetic form (thymalfasin) used pharmaceutically in certain countries. Not approved by the U.S. FDA for general therapeutic use; treated here as a research-use-only compound for educational purposes.

This profile summarizes research context only. It is not medical advice and does not describe how to use this compound in humans or animals — no dosing, administration, or protocols. Learn more

This entry is a draft pending editorial and source verification. It is excluded from search indexing until reviewed.

Thymosin Alpha-1 (Tα1, also referred to in pharmaceutical contexts as thymalfasin) is a 28-amino-acid peptide derived from prothymosin alpha and originally characterized from thymic tissue. It is discussed in the research literature primarily as an immunomodulator, with reported effects on innate and adaptive immune signaling described mainly in vitro, in animal models, and in some clinical investigations conducted outside the United States. The evidence base is heterogeneous and should be interpreted cautiously given variation in study design, endpoints, and translational limitations. This profile is educational and for research-use context only; it is not a recommendation for human or animal use, and it makes no claim that the compound treats, prevents, or cures any condition.

Mechanism as described in the literature

Thymosin Alpha-1 is a naturally occurring 28-amino-acid fragment of prothymosin alpha, first isolated from thymic tissue (thymosin fraction 5). In the research literature it is characterized as an immunomodulatory peptide reported to interact with innate-immune receptors, including Toll-like receptors such as TLR2 and TLR9, and is described in preclinical models as influencing dendritic-cell maturation, T-cell differentiation, natural-killer-cell activity, and the balance of signaling cytokines (for example interferons and interleukins).

These mechanisms are described predominantly in vitro and in animal studies, alongside a clinical research record that remains heterogeneous in design, endpoints, and quality. Mechanistic descriptions do not establish clinical benefit, and how such signaling effects translate to outcomes in humans remains uncertain and an active area of study requiring careful interpretation.

Research areas

Immune modulation and innate/adaptive immune signaling (mechanistic and preclinical)
Antiviral and vaccine-adjuvant research contexts (including chronic viral hepatitis study settings)
Cytokine, T-cell, and dendritic-cell biology described in vitro
Immuno-oncology research contexts (described as investigational)
Sepsis and immune-dysregulation research models

Known limitations

Much of the supporting evidence is preclinical (in vitro and animal); available human data are heterogeneous and vary in design, endpoints, and quality.
Clinical research has largely been conducted outside the United States and under conditions that may limit generalizability.
Mechanistic findings do not establish safety or efficacy for any condition and should not be read as evidence of clinical benefit.
Terminology and product identity vary between sources (e.g., 'Thymosin Alpha-1' versus the pharmaceutical designation 'thymalfasin'), and the name is sometimes conflated with unrelated beta-thymosins, so source and identity verification is required.
No citations, purity figures, certificates of analysis, or vendor data are asserted in this draft; all sources must be independently verified by a human editor.

Documentation notes

References

References for this entry are pending editorial verification. We do not publish citations we have not confirmed.

Frequently asked questions

What is Thymosin Alpha-1?+

It is a 28-amino-acid peptide derived from prothymosin alpha that is discussed in the research literature as an immunomodulator; a synthetic form is also referred to as thymalfasin. This profile is educational and is not a recommendation for use in humans or animals.

Is Thymosin Alpha-1 the same as thymosin beta-4 (TB-500)?+

No. Despite the shared 'thymosin' name, Thymosin Alpha-1 and the beta-thymosins such as thymosin beta-4 are distinct molecules with different sequences and different reported mechanisms. Some sources conflate them, so confirming molecular identity is important.

What does the current evidence show?+

The literature describes immune-signaling mechanisms largely in vitro and in animal models, alongside a heterogeneous clinical research record. The evidence is limited and should be interpreted cautiously; it does not establish that the compound treats, prevents, or cures anything.